ClinicalTrials.gg
CompletedNCT05692154FEXPRESARUpdated Sep 9, 2025Results posted

A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

A Phase 3 interventional study of Fexofenadine and Placebo in Seasonal Allergic Rhinitis, sponsored by Opella Healthcare Group SAS, a Sanofi Company. Completed at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Opella Healthcare Group SAS, a Sanofi Company (formerly part of Sanofi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada — 2 open to participants now, 3 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Canada.

Enrollment
19th of 32
95 · median 104
Started
2023
with 3 others
Phase 3
6 of 33
none open now
Registered
25th of 33
by date

Among the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, this one is the 19th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 in phase 3, and was the 25th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

2 of the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, or all of them as a file.
02

Study summary

This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms.

The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.

Read the detailed description

The end of the study is defined as the date of the last visit of the last participant in the study.

A participant is considered to have completed the study if he/she has completed all visits of the study including Visit 5 (Day 5).

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Participant is willing to provide written .
  • Adult participants (18 to 80 years old) suffering from seasonal allergic rhinitis (SAR) provoked by Ragweed pollen.
  • Participants having a total nasal symptom score (TNSS)-3 ≥4 (with 3 nasal symptoms) at first pollen challenge at Visit 2.
  • Having a 2-year history of SAR with Positive skin prick test to Ragweed allergen at screening (with a wheal diameter at least 3 mm larger than that produced by the negative control).

Exclusion criteria

Exclusion Criteria:

  • History of anaphylaxis to Ragweed pollen History of asthma or exacerbations in the past 12 months requiring regular inhaled for greater than 4 weeks per year, any oral corticosteroid usage, any emergency department visit for asthma or any asthma-related hospitalization. Mild asthmatics treated only with pro re nata short-acting β2agonists, less than 2 doses per week can be enrolled.
  • History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness.
  • History of systemic disease affecting the immune system such as diseases, immune complex disease, or immunodeficiency, where, in the opinion of the study physician, participation in the trial would pose a risk or significant effect on the immune system.
  • Presence or history of drug to fexofenadine and/or its .
  • Participants unable to stop the following forbidden treatments/nutriments prior to pollen challenge:

    • Antihistamines: within 3 days for first-generation antihistamines, within 2 days for second-generation antihistamines.
    • Intranasal or inhaled corticosteroids: 7 days.
    • Ocular, intranasal, or inhaled sodium cromoglycate: 14 days.
    • High doses of systemic corticosteroids: 30 days.
    • Leukotriene antagonists: 30 days.
    • Intranasal or systemic decongestants: 3 days.
    • Tricyclic antidepressants: 7 days.
    • Any citrus fruits (grapefruit, orange, etc.) or their juices, as well as all fruit juices: 5 days.
    • Aluminum-and-magnesium containing antacids: 7 days.
    • Omalizumab/dupilumab: within 6 months
  • Any to fexofenadine, according to the labeling.
  • The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Arm A (active-active)

    Two days of pre-treatment with Fexofenadine 180 mg each day in the morning on Day 2 and Day 3, then Fexofenadine180 mg after the pollen challenge on Day 4.

    Drug: Fexofenadine

  • Experimental
    Arm B (placebo-active)

    Two days of pre-treatment with tablet of matching placebo each day in the morning on Day 2 and Day 3, then Fexofenadine180 mg after the pollen challenge on Day 4.

    Drug: Placebo

Interventions

  • Fexofenadine oral tablet

  • DrugPlacebo

    Fexofenadine matching placebo oral tablet

06

What researchers measure

Primary outcomes

  1. Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)

    TNSS-3=composite score calculated as sum of rhinorrhea, sneezing, and nasal itching scores (TNSS-3: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. Individual scores were collected in e-diary. AUC of TNSS from time of the first observation to time of the last observation (AUC \[0-6 hr\]) was calculated by using the linear trapezoid method. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-43.5; Arm B=2.1-39.9.

    Time frame: From 0 hour to 6 hours at Day 4

Secondary outcomes

  1. AUC of Total Ocular Symptoms Score (TOSS) (H0-H6 at Day 4)

    TOSS=composite score calculated as the sum of red/burning eyes, tearing, itchy/watery eyes scores (TOSS: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. individual scores were collected in e-diary. AUC of TOSS from time of the first observation to time of the last observation (AUC \[0-6 hr\]) was calculated by using the linear trapezoid. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-43.6; Arm B=0.0-35.1.

    Time frame: From 0 hour to 6 hours at Day 4

  2. AUC of Total Nasal Symptoms Score (TNSS-3) (H0-H12 at Day 4)

    TNSS-3=composite score calculated as sum of rhinorrhea, sneezing, and nasal itching scores (TNSS-3: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. Individual scores were collected in e-diary. AUC of TNSS from time of the first observation to time of the last observation (AUC \[0-12 hr\]) was calculated by using the linear trapezoid method. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-63.5; Arm B=2.1-69.4.

    Time frame: From 0 hour to 12 hours at Day 4

  3. AUC of Total Ocular Symptoms Score (TOSS) (H0-H12 at Day 4)

    TOSS=composite score calculated as the sum of red/burning eyes, tearing, itchy/watery eyes scores (TOSS: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. individual scores were collected in e-diary. AUC of TOSS from time of the first observation to time of the last observation (AUC \[0-12 hr\]) was calculated by using the linear trapezoid. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-58.6; Arm B=0.0-65.5.

    Time frame: From 0 hour to 12 hours at Day 4

  4. AUC of Total Nasal Symptoms Score (TNSS-3) (Day 1 to Day 4)

    TNSS-3=composite score calculated as sum of rhinorrhea, sneezing, and nasal itching scores (TNSS-3:scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. Individual scores were collected in e-diary. AUC of TNSS from time of the first observation to time of the last observation (AUC \[Day 1 to Day 4\]) was calculated by using the linear trapezoid method. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-267.8; Arm B=2.1-379.0.

    Time frame: From randomization (Day 1) to Day 4

  5. AUC of Total Ocular Symptoms Score (TOSS) (Day 1 to Day 4)

    TOSS=composite score calculated as the sum of red/burning eyes, tearing, itchy/watery eyes scores (TOSS: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. individual scores were collected in e-diary. AUC of TOSS from time of the first observation to time of the last observation (AUC \[Day 1 to Day 4\]) was calculated by using the linear trapezoid. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-226.6; Arm B=0.0-304.5.

    Time frame: From randomization (Day 1) to Day 4

  6. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the study. A treatment emergent adverse event (TEAE) is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state.

    Time frame: From Day 2 to Day 5

07

Results

Posted May 16, 2024

Participant flow

A total of 95 participants took part in the study at one investigative site in Canada from 23 January 2023 to 14 March 2023.

Participant flow — Overall Study
MilestoneArm A (Active-active)Arm B (Placebo-active)
Started4748
Intent to treat (itt) analysis set4748
Safety analysis (saf) set4747
Modified intent-to-treat (mitt) analysis set4747
Completed4747
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryArea Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)

TNSS-3=composite score calculated as sum of rhinorrhea, sneezing, and nasal itching scores (TNSS-3: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. Individual scores were collected in e-diary. AUC of TNSS from time of the first observation to time of the last observation (AUC \[0-6 hr\]) was calculated by using the linear trapezoid method. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-43.5; Arm B=2.1-39.9.

Time frame:
From 0 hour to 6 hours at Day 4
Reported as:
Mean · Sum of scores*hours
Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)
Sum of scores*hoursArm A (Active-active)Arm B (Placebo-active)
Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)16.96 ± 9.09021.42 ± 10.431
Statistical analysis
  • Arm A (Active-active) vs Arm B (Placebo-active) · ANCOVA · p = 0.038 · Least square mean difference: -4.24 · 95% CI -8.24 to -0.23Least-squares means, standard errors and p-value are taken from an analysis of covariance model, with treatment group as fixed effect and baseline TNSS (H0 at Visit 4) as covariate.
SecondaryAUC of Total Ocular Symptoms Score (TOSS) (H0-H6 at Day 4)

TOSS=composite score calculated as the sum of red/burning eyes, tearing, itchy/watery eyes scores (TOSS: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. individual scores were collected in e-diary. AUC of TOSS from time of the first observation to time of the last observation (AUC \[0-6 hr\]) was calculated by using the linear trapezoid. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-43.6; Arm B=0.0-35.1.

Time frame:
From 0 hour to 6 hours at Day 4
Reported as:
Mean · Sum of scores*hours
AUC of Total Ocular Symptoms Score (TOSS) (H0-H6 at Day 4)
Sum of scores*hoursArm A (Active-active)Arm B (Placebo-active)
AUC of Total Ocular Symptoms Score (TOSS) (H0-H6 at Day 4)11.74 ± 10.45116.21 ± 11.253
Statistical analysis
  • Arm A (Active-active) vs Arm B (Placebo-active) · ANCOVA · p = 0.025 · Least square mean difference: -4.75 · 95% CI -8.90 to -0.60Least-squares means, standard errors and p-value are taken from an analysis of covariance, with treatment group as fixed categorical effect and baseline TOSS (H0 at Visit 4) as covariate.
SecondaryAUC of Total Nasal Symptoms Score (TNSS-3) (H0-H12 at Day 4)

TNSS-3=composite score calculated as sum of rhinorrhea, sneezing, and nasal itching scores (TNSS-3: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. Individual scores were collected in e-diary. AUC of TNSS from time of the first observation to time of the last observation (AUC \[0-12 hr\]) was calculated by using the linear trapezoid method. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-63.5; Arm B=2.1-69.4.

Time frame:
From 0 hour to 12 hours at Day 4
Reported as:
Mean · Sum of scores*hours
AUC of Total Nasal Symptoms Score (TNSS-3) (H0-H12 at Day 4)
Sum of scores*hoursArm A (Active-active)Arm B (Placebo-active)
AUC of Total Nasal Symptoms Score (TNSS-3) (H0-H12 at Day 4)23.66 ± 14.04931.01 ± 18.555
Statistical analysis
  • Arm A (Active-active) vs Arm B (Placebo-active) · ANCOVA · p = 0.048 · Least square mean difference: -6.50 · 95% CI -12.95 to -0.05Least-squares means, standard errors and p-value are taken from an analysis of covariance model, with treatment group as fixed effect and baseline TNSS (H0 at Visit 4) as covariate.
SecondaryAUC of Total Ocular Symptoms Score (TOSS) (H0-H12 at Day 4)

TOSS=composite score calculated as the sum of red/burning eyes, tearing, itchy/watery eyes scores (TOSS: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. individual scores were collected in e-diary. AUC of TOSS from time of the first observation to time of the last observation (AUC \[0-12 hr\]) was calculated by using the linear trapezoid. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-58.6; Arm B=0.0-65.5.

Time frame:
From 0 hour to 12 hours at Day 4
Reported as:
Mean · Sum of scores*hours
AUC of Total Ocular Symptoms Score (TOSS) (H0-H12 at Day 4)
Sum of scores*hoursArm A (Active-active)Arm B (Placebo-active)
AUC of Total Ocular Symptoms Score (TOSS) (H0-H12 at Day 4)14.74 ± 14.43221.67 ± 17.154
Statistical analysis
  • Arm A (Active-active) vs Arm B (Placebo-active) · ANCOVA · p = 0.011 · Least square mean difference: -7.47 · 95% CI -13.21 to -1.73Least-squares means, standard errors and p-value are taken from an analysis of covariance, with treatment group as fixed categorical effect and baseline TOSS (H0 at Visit 4) as covariate.
SecondaryAUC of Total Nasal Symptoms Score (TNSS-3) (Day 1 to Day 4)

TNSS-3=composite score calculated as sum of rhinorrhea, sneezing, and nasal itching scores (TNSS-3:scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. Individual scores were collected in e-diary. AUC of TNSS from time of the first observation to time of the last observation (AUC \[Day 1 to Day 4\]) was calculated by using the linear trapezoid method. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-267.8; Arm B=2.1-379.0.

Time frame:
From randomization (Day 1) to Day 4
Reported as:
Mean · Sum of scores*hours
AUC of Total Nasal Symptoms Score (TNSS-3) (Day 1 to Day 4)
Sum of scores*hoursArm A (Active-active)Arm B (Placebo-active)
AUC of Total Nasal Symptoms Score (TNSS-3) (Day 1 to Day 4)56.34 ± 55.69765.48 ± 76.454
Statistical analysis
  • Arm A (Active-active) vs Arm B (Placebo-active) · ANCOVA · p = 0.074 · Least square mean difference: -18.45 · 95% CI -38.74 to 1.83Least-squares means, standard errors and p-value are taken from an analysis of covariance, with treatment group as fixed categorical effect and baseline TNSS (Day 1) as covariate.
SecondaryAUC of Total Ocular Symptoms Score (TOSS) (Day 1 to Day 4)

TOSS=composite score calculated as the sum of red/burning eyes, tearing, itchy/watery eyes scores (TOSS: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. individual scores were collected in e-diary. AUC of TOSS from time of the first observation to time of the last observation (AUC \[Day 1 to Day 4\]) was calculated by using the linear trapezoid. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-226.6; Arm B=0.0-304.5.

Time frame:
From randomization (Day 1) to Day 4
Reported as:
Mean · Sum of scores*hours
AUC of Total Ocular Symptoms Score (TOSS) (Day 1 to Day 4)
Sum of scores*hoursArm A (Active-active)Arm B (Placebo-active)
AUC of Total Ocular Symptoms Score (TOSS) (Day 1 to Day 4)39.51 ± 55.41647.21 ± 69.443
Statistical analysis
  • Arm A (Active-active) vs Arm B (Placebo-active) · ANCOVA · p = 0.729 · Least square mean difference: -4.06 · 95% CI -27.24 to 19.12Least-squares means, standard errors and p-value are taken from an analysis of covariance, with treatment group as fixed categorical effect and baseline TOSS (H0 at Day 1) as covariate.
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the study. A treatment emergent adverse event (TEAE) is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state.

Time frame:
From Day 2 to Day 5
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
percentage of participantsArm A (Active-active)Arm B (Placebo-active)
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)19.112.8

Adverse events

Collected over From Day 2 to Day 5. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Active-active)0/47 (0%)0/47 (0%)9/47 (19.1%)
Arm B (Placebo-active)0/47 (0%)0/47 (0%)6/47 (12.8%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventArm A (Active-active)Arm B (Placebo-active)
Oedema mucosalGeneral disorders2/470/47
HeadacheNervous system disorders2/472/47
Nasal obstructionRespiratory, thoracic and mediastinal disorders2/471/47
TinnitusEar and labyrinth disorders0/471/47
Seasonal allergyImmune system disorders1/470/47
GastroenteritisInfections and infestations0/471/47
Skin abrasionInjury, poisoning and procedural complications1/470/47
ArthralgiaMusculoskeletal and connective tissue disorders1/470/47
Back painMusculoskeletal and connective tissue disorders1/470/47
MyalgiaMusculoskeletal and connective tissue disorders0/471/47

Baseline characteristics

The mITT analysis set contained all eligible, ITT, and treated participants with Total Nasal Symptom Score of 3 symptoms (TNSS-3) evaluation Hour 0 (H0) at visit 4 (V4) and at least a further time point at Visit 4.

Age, Continuous
Age, Continuous(years)Arm A (Active-active)Arm B (Placebo-active)Total
Mean47.0 ± 12.8244.7 ± 13.0545.9 ± 12.92
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Active-active)Arm B (Placebo-active)Total
Female343468
Male131326
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A (Active-active)Arm B (Placebo-active)Total
Hispanic or Latino011
Not Hispanic or Latino474693
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Active-active)Arm B (Placebo-active)Total
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American000
White414586
More than one race000
Unknown or Not Reported415
08

Study locations

1 site
  • Investigational Site Number : 1240001
    Kingston, Ontario K7L 2V7, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Mar 2023, 1 month.

Results were first posted in May 2024, 1 year 2 months after primary completion.

Of 31 industry-sponsored phase 3 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 1 month is below that.

Counting every sponsor, half of 37 studies reached it within 4 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Jan 20, 2023
StartActual
Jan 23, 2023
Primary completionActual
Mar 14, 2023
CompletionActual
Mar 14, 2023
Results first posted
May 16, 2024
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05692154
Responsible party
Sponsor
First posted
Jan 20, 2023
Start date
Jan 23, 2023
Primary completion
Mar 14, 2023
Completion
Mar 14, 2023
Results posted
May 16, 2024
Last update
Sep 9, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexofenadine

Start the discussion